Skip to main contentSkip to navigation
Sirius Investors

ADC Therapeutics S.A. (ADCT) Investment Research Dashboard

About ADC Therapeutics S.A. (ADCT) stock analysis

Get live ADCT stock price $1.15, comprehensive ADC Therapeutics S.A. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ADCT stock data and investment insights.

1.15
5.74%Today
Market Cap
146.27M
Volume
546.13K
52W High
4.98
52W Low
0.78

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being eva...

Company Information

CEO
Ameet Mallik
Sector
Healthcare
Industry
Biotechnology
Employees
188

Contact Information

Address
Biopole
Country
CH

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 1.88)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for ADC Therapeutics S.A. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for ADC Therapeutics S.A.
  • Investors should consider how ADC Therapeutics S.A. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

146.27M

P/E Ratio (TTM)

-1.10

Beta

1.88

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

77/100 ⭐⭐⭐⭐⭐

Overall
+0.3%
NYSE
+0.7%
NASDAQ
-0.2%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.5%+2.2%19.1
82/100⭐⭐⭐⭐⭐
Healthcare+0.3%+2.7%+1.5%23.5
77/100⭐⭐⭐⭐⭐
Real Estate+1.8%+4.6%+0.7%29.8
72/100⭐⭐⭐⭐⭐
Communication Services+0.7%-2.1%+2.2%21.8
70/100⭐⭐⭐⭐⭐
Basic Materials+0.9%+2.0%-0.3%25.0
60/100⭐⭐⭐⭐
Consumer Defensive+0.8%+1.0%-0.2%28.7
55/100⭐⭐⭐⭐
Utilities-0.7%+2.5%-1.9%25.2
49/100⭐⭐⭐
Energy-0.2%-0.4%-2.4%19.6
42/100⭐⭐⭐
Consumer Cyclical+0.3%-1.6%-4.0%43.3
17/100
Industrials-0.5%-0.1%-8.9%30.4
15/100
Technology-1.6%-0.8%-5.3%42.2
12/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-27.